MarginsXMarginsX
Home › Markets › Health Care › JAZZ

Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ)

JAZZ trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$239.77
-0.74% on the day
Market cap
$15.4B
Large cap
Revenue · 2025
$4.3B
+4.9% on 2024
Net income · 2025
-$356.1M
-8.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/0001232524-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerJAZZ on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIreland
IPO year2007
SEC CIK0001232524
SEC industry codePharmaceutical Preparations
Incorporated inIreland

Financials · 2025

LineValue
Revenue$4.3B
Net income-$356.1M
Operating income-$430.2M
Net margin-8.3%
Operating margin-10.1%
Revenue growth+4.9%
Cash$1.4B
Total assets$11.7B
P/E (computed)Net income was not positive
P/S (computed)3.6×

Warning signs

Cash runway
Cash-flow positive
$2.0B cash at September 30, 2026
Share count, 1 year
+5.6%
2025-10-29 to 2026-10-26 · +2.0% over 3 years
Going-concern doubt
No
10-Q filed November 2, 2026
Insider net buying, 12 months
-$68.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-02
Cash and burn$2.0B cash; operating cash flow $423.1M a quarter.Report 2026-09-30
Shares outstanding64,189,052 (2026-10-26); 60,765,116 a year earlier; 62,956,913 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG, Dublin, IrelandPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $68.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.2B-$483.4M$506.1M$2.0B$5.6B$4.7B10-Q 2026-11-02
Q2 2026
2026-06-30
$1.2B$192.8M$415.7M$1.6B$4.4B$4.6B10-Q 2026-08-03
Q1 2026
2026-03-31
$1.1B$293.1M$408.2M$1.8B$5.4B$4.4B10-Q 2026-05-05
Q4 2025
2025-12-31
$1.2B$203.5M$362.5M$1.4B$5.4B$4.3B10-K 2026-02-24
Q3 2025
2025-09-30
$1.1B$251.4M$474.7M$1.3B$5.4B$4.2B10-Q 2026-11-02
Q2 2025
2025-06-30
$1.0B-$718.5M$88.8M$1.2B$5.4B$4.1B10-Q 2026-08-03
Q1 2025
2025-03-31
$897.8M-$92.5M$429.8M$1.9B$5.4B$4.1B10-Q 2026-05-05
Q4 2024
2024-12-31
$1.1B$191.1M$398.6M$2.4B$6.1B$4.1B10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report10-K/A2026-04-24
Latest quarterly / interim10-Q2026-11-02
Latest current report8-K2026-11-02
Latest proxyDEFA14A2026-07-14

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.9%
1 month+14.8%
3 months-1.7%
Year to date+42.1%
1 year+70.5%
From 52-week high-7.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BBIOBridgeBio Pharma Inc.$77.36-1.20%$15.1B
ASNDAscendis Pharma A/S Ordinary Share$271.73-1.33%$17.9B
ELANElanco Animal Health Incorporated$26.41-1.38%$13.2B
RDYDr. Reddy's Laboratories Ltd$14.70-0.27%$12.3B
BMRNBioMarin Pharmaceutical Inc.$57.99+1.33%$11.2B
ALNYAlnylam Pharmaceuticals Inc.$159.73-3.22%$21.4B
VTRSViatris Inc.$20.74-0.38%$23.8B
MDGLMadrigal Pharmaceuticals Inc.$423.96-0.80%$9.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier